RESEARCH ARTICLE

Prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteria isolated from urban and rural folks in Uganda

[version 1; peer review: 1 approved, 2 approved with reservations]

Christine F Najjuka ^{1*}, David Patrick Kateete ^{1,2*}, Dennis K Lodiongo^{1,3}, Obede Mambo^{1,4}, Chunderika Mocktar⁵, William Kayondo⁶, Hannington Baluku¹, Henry M Kajumbula¹, Sabiha Y Essack ⁵, Moses L Joloba^{1,2}

¹Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda

²Department of Immunology & Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda

³Ministry of Health Public Health Laboratory, National Blood Bank and Transfusion services Centre, Juba, Sudan

⁴Rumbek Health Science Institute, Lakes State, Sudan

⁵Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu Natal, Westville, Durban, South Africa

⁶Makerere University Walter Reed Project, Box 16524, Kampala, Uganda

* Equal contributors

V1 First published: 30 Nov 2020, 3:62
<https://doi.org/10.12688/aasopenres.13165.1>
 Latest published: 30 Nov 2020, 3:62
<https://doi.org/10.12688/aasopenres.13165.1>

Abstract

Background: AmpC beta-lactamase-producing bacteria are associated with increased resistance to third-generation cephalosporins. Here, we describe plasmid-mediated AmpC beta-lactamase-producing enterobacteria isolated from urban and rural dwellers in Uganda.

Methods: Stool and urine from 1,448 individuals attending outpatient clinics in Kampala and two rural districts in central Uganda were processed for isolation of *Escherichia coli* and Klebsiella. Following antibiotic susceptibility testing, cefoxitin resistant isolates, and amoxicillin/clavulanate resistant but cefoxitin susceptible isolates, were tested for AmpC beta-lactamase production using the cefoxitin-cloxacillin double-disc synergy test. Carriage of plasmid-mediated AmpC beta-lactamase-encoding genes (pAmpC) and extended spectrum beta-lactamase (ESBL) encoding genes was determined by PCR.

Results: Nine hundred and thirty *E. coli* and 55 Klebsiella were recovered from the cultured samples, yielding 985 isolates investigated (one per participant). One hundred and twenty-nine isolates (13.1%, 129/985) were AmpC beta-lactamase producers, of which 111 were molecularly characterized for pAmpC and ESBL gene carriage. pAmpC genes were detected in 60% (67/111) of the AmpC

Open Peer Review

Approval Status ? ✓ ?

	1	2	3
version 1	?	✓	?
30 Nov 2020	view	view	view
1. Soo Tein Ngoi , University Malaya, Kuala Lumpur, Malaysia			
2. Samuel Kariuki , Kenya Medical Research Institute, Nairobi, Kenya			
Robert Onsare , Kenya Medical Research Institute (KEMRI), Nairobi, Kenya			
3. Muhammad Usman Qamar , Government College University, Faisalabad, Pakistan			

Any reports and responses or comments on the article can be found at the end of the article.

beta-lactamase producers; pAmpC genes were also detected in 18 AmpC beta-lactamase non-producers and in 13 isolates with reduced susceptibility to third-generation cephalosporins, yielding a total of 98 isolates that carried pAmpC genes. Overall, the prevalence of pAmpC genes in cefoxitin resistant and/or amoxicillin/clavulanate resistant *E. coli* and *Klebsiella* was 59% (93/157) and 26.1% (5/23), respectively. The overall prevalence of pAmpC-positive enterobacteria was 10% (98/985); 16.4% (45/274) in Kampala, 6.2% (25/406) Kayunga, and 9.2% (28/305) Mpigi. Ciprofloxacin use was associated with carriage of pAmpC-positive bacteria while residing in a rural district was associated with protection from carriage of pAmpC-positive bacteria.

Conclusion: pAmpC beta-lactamase producing enterobacteria are prevalent in urban and rural dwellers in Uganda; therefore, cefoxitin should be considered during routine susceptibility testing in this setting.

Keywords

Enterobacteriaceae, *Escherichia coli*, *Klebsiella*, Urban-Rural, Kampala-Uganda

Corresponding authors: Christine F Najjuka (najjukafc@gmail.com), David Patrick Kateete (dkateete@chs.mak.ac.ug)

Author roles: **Najjuka CF:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Kateete DP:** Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Lodiongo DK:** Investigation; **Mambo O:** Investigation; **Mocktar C:** Data Curation, Formal Analysis, Investigation, Methodology; **Kayondo W:** Investigation; **Baluku H:** Methodology; **Kajumbula HM:** Investigation, Methodology; **Essack SY:** Conceptualization, Methodology, Supervision, Writing – Review & Editing; **Joloba ML:** Methodology, Resources, Supervision, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported in part by the African Academy of Sciences (AAS) through a DELTAS Africa Initiative grant awarded to DPK [107743/Z/15/Z]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA), and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107743/Z/15/Z] and the UK Government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. This work was also supported in part with funds from the Swedish International Development Agency (SIDA). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2020 Najjuka CF *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Najjuka CF, Kateete DP, Lodiongo DK *et al.* **Prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteria isolated from urban and rural folks in Uganda [version 1; peer review: 1 approved, 2 approved with reservations]** AAS Open Research 2020, 3:62 <https://doi.org/10.12688/aasopenres.13165.1>

First published: 30 Nov 2020, 3:62 <https://doi.org/10.12688/aasopenres.13165.1>

Introduction

Enterobacteriaceae is a family of Gram-negative bacteria that inhabit the mammalian gut and includes the leading causes of community- and hospital-acquired infections¹. Enterobacteriaceae have become increasingly resistant to antibiotics, especially beta (β)-lactam agents, the mainstay of treatment for infections caused by them. One of the main mechanisms underlying resistance to β -lactam antibiotics among the enterobacteriaceae are the AmpC β -lactamases. These enzymes are clinically relevant as they confer resistance to most β -lactam antibiotics, except the fourth-generation cephalosporins and carbapenems²⁻⁴.

AmpC β -lactamases are chromosomally encoded in most species of the enterobacteriaceae, particularly *Citrobacter freundii*, *Enterobacter*, *Morganella morganii*, *Hafnia alvei*, *Aeromonas* and *Serratia* spp.³. However, *Escherichia coli* and other enterobacteria, notably *Proteus mirabilis*, *Salmonella* and *Klebsiella* spp., can acquire plasmid-encoded AmpC β -lactamases (pAmpC), which are highly transferable between species. Note that *Proteus mirabilis*, *Salmonella* and *Klebsiella* spp. lack chromosomally-encoded AmpC enzymes, while a chromosomally-encoded AmpC β -lactamase occurs in *E. coli* but it is expressed at low basal levels due to presence of a weak promoter and attenuator, which makes *E. coli* susceptible to cephamycins (e.g. cefoxitin, cefotetan)^{2,5,6}. Acquisition of pAmpC β -lactamases by species like *E. coli* and *Klebsiella pneumoniae* (*K. pneumoniae*) is worrying as it enables an efficient spread of extended resistance in bacteria and ultimately their spread in the community³. Furthermore, the widespread use of cephamycins and β -lactamase inhibitor combinations (e.g. clavulanic acid/amoxicillin and tazobactam/piperacillin) has contributed to selection of pAmpC β -lactamase producing strains worldwide^{7,8}.

Once they have colonized the gut, pAmpC β -lactamase producing strains may initiate an infection at various anatomical sites⁹. In low-income countries where such infections are empirically treated with third-generation cephalosporins, failure to detect AmpC β -lactamase-related resistance may lead to treatment failure. Moreover, the cut-off / break points for the disc diffusion / minimum inhibitory concentrations (MICs) may not detect AmpC β -lactamase production and resistance to third-generation cephalosporins. Carbapenems are currently the only effective drugs against infections caused by AmpC β -lactamase producing bacteria, since these bacteria tend to be multidrug resistant (MDR)¹⁰. However, carbapenamase-producing enterobacteria are now common in low-income countries including Uganda¹¹.

Although pAmpC β -lactamase producing bacteria have been reported throughout the world^{3,7,12,13}, there is little information about them in Uganda, especially their frequency among enterobacteria. Therefore, the aim of this study was to estimate the prevalence of pAmpC β -lactamase producing bacteria among Enterobacteriaceae isolated from individuals attending outpatient clinics in Kampala city and two rural districts in central Uganda. We show that pAmpC β -lactamase producing bacteria are prevalent in enterobacteriaceae isolated from urban and rural dwellers in Uganda, implying that ceftriaxone, an antibiotic commonly used to treat systemic infections in Uganda, could be associated with treatment failure.

Methods

Study setting

This cross-sectional study was conducted on flora from stool and urine of clients attending outpatients clinics in Kampala and two rural districts (Kayunga and Mpigi) in central Uganda¹⁴. The study sites were purposively selected with an assumption that urban areas are associated with high bacterial carriage and exposure to antibiotics compared to rural areas¹⁵. Kampala (urban) and Mpigi districts were assumed to have a wet-tropical climate, while Kayunga has a wet-dry tropical climate¹⁶.

Sample size estimation and sampling

The sample size for each study subsite was proportional to the contribution of the facility to the total outpatient clinic attendance in the months of April, May and June of 2006. All individuals attending the clinics were eligible to participate. By then, there was no data on antibiotic resistance among *E. coli* and/or *K. pneumoniae* isolates in well-defined community infections in Uganda. As such, the sample size was estimated based on an observed prevalence of 19.6% for *K. pneumoniae* carriage in clinical samples (urine, etc.) at Makerere University's Clinical Microbiology Laboratory (unpublished observations). In each of the three districts, multistage sampling was done based on the average clinic attendance for the district. Thirty clusters of 16–20 participants were selected from each district using probability proportion to size sampling. Two busy days of a week were purposively chosen to visit a selected health care facility. When the number of participants exceeded 20, systematic sampling was done. A standardized interviewer-administered questionnaire was used to collect clinical and demographic data. Participants were instructed to provide stool or urine (if unable to provide stool) in a sterile screw-cap container. Samples from the rural districts were stored at 4°C for up to 24 hours prior to transportation, while those from Kampala were immediately transported to the laboratory at Makerere University College of Health Sciences for culturing.

Culturing and identification of *E. coli* and *K. pneumoniae*

The procedure for culturing and isolate identification was described previously¹⁴. Briefly, samples were streaked on MacConkey agar medium on the third/fourth quadrant, and incubated at 37°C for 18–24 hours in ambient air. In case of stool, samples were first emulsified in sterile normal saline before inoculation onto MacConkey agar plates. Lactose fermenting isolates with colony morphology suggestive of *E. coli* and *Klebsiella* spp. were subjected to oxidase testing and when negative, they were cultured for 18–24 hours on triple sugar and iron (TSI) agar, Simmons citrate agar, urea and Sulphide Indole Motility (SIM) medium for identification. Inconclusive isolates were confirmed as *E. coli* or *Klebsiella* by using the API 20E system (BioMerieux Marcy l'Etoile, France).

Antibiotic susceptibility testing

Antibiotic susceptibility testing (AST) was performed with the disc diffusion tests (DDT) on Mueller Hinton Agar (MHA) (Biolab, Hungary) as recommended by the Clinical Laboratory Standards Institute (CLSI)¹⁷. Bacterial suspensions equivalent to 0.5 McFarland standard were prepared. The DDT included antibiotic disks (Biolab, Hungary) of ampicillin (10 μ g),

amoxicillin/clavulanate (20/10 µg), cefuroxime (30 µg), ceftriaxone (30 µg), cefotaxime (30 µg), ceftazidime (30 µg), meropenem (30 µg), sulfamethoxazole/trimethoprim (co-trimoxazole) (23.75/1.25 µg), chloramphenicol (30 µg), gentamicin (10 µg), ciprofloxacin (5 µg), nitrofurantoin (300 µg), cefepime (30 µg), piperacillin/tazobactam (100/10 µg) and ceftiofur (30 µg). *E. coli* ATCC25992, *Staphylococcus aureus* ATCC29213, *Pseudomonas aeruginosa* ATCC27853 and *Enterococcus faecalis* ATCC29212 were used as quality controls.

Testing for AmpC β-lactamase production

Typically, AmpC β-lactamases confer resistance to cephamycins (e.g. ceftiofur), a characteristic widely used to distinguish them from the extended-spectrum β-lactamases (ESBLs), and to functionally screen for AmpC β-lactamase producing isolates^{3,4,18–21}. As such, all ceftiofur resistant isolates in this study were screened by the ceftiofur/cloxacillin double-disc synergy test (CC-DDST) to detect AmpC β-lactamase production as previously described²². As AmpC β-lactamases are associated with clavulanate resistance^{17,23}, isolates with reduced susceptibility to amoxicillin/clavulanate were also tested for AmpC β-lactamase production. Susceptibility to ceftiofur and to third-generation cephalosporins was determined based on the CLSI guidelines (2007)²⁴. Furthermore, isolates that were positive on the CC-DDST (i.e. AmpC β-lactamase producers) were re-tested with E-test strips containing cefotetan and cefotetan/cloxacillin (CN/CNI, AB BIODISC, Solna, Sweden). E-test screening was considered positive for AmpC β-lactamase production when MIC ratio for cefotetan / cefotetan/cloxacillin was ≥ 8 ²². Testing for ESBL production was carried out as described previously²⁵, on isolates with reduced zone diameters to third-generation cephalosporins. Briefly, isolates with zone diameters of 22 mm, 25 mm, 27 mm and 27 mm for discs of ceftazidime, ceftriaxone, cefotaxime and aztreonam respectively, were considered suspect for ESBL-production, which was subsequently confirmed by the double disc synergy test (DDST). Detection of ESBLs was The DDST for detection of ESBLs was performed by using amoxicillin/clavulanate disc in the center, and discs of ceftazidime, ceftriaxone, aztreonam, and cefotaxime placed 15–20 mm center-to-center from the amoxicillin-clavulanate disc. Extension of the zone of inhibition towards the clavulanate disc was indicative of ESBL-production.

Screening for ESBL and pAmpC β-lactamase genes

All isolates testing positive for AmpC β-lactamase production on the CC-DDST were tested by polymerase chain reaction (PCR) for pAmpC gene carriage. Further, as pAmpC β-lactamase genes have also been detected in isolates with reduced susceptibility to third-generation cephalosporins, we tested isolates with inhibition zone diameters of ≤ 27 mm, ≤ 25 mm and ≤ 22 mm for cefotaxime, ceftriaxone and ceftazidime, respectively, for pAmpC gene carriage^{17,23}. In-house multiplex PCRs targeting AmpC β-lactamase genes *bla*_{CIT}, *bla*_{DHA}, *bla*_{MOX}, *bla*_{FOX}, *bla*_{EBC}, *bla*_{ACC} and *bla*_{CMY-2} were performed using published primers, Thermo-Fisher Taq DNA polymerase and PCR master-mixes, and conditions^{6,26}. Amplification was performed in a 3Prime Mid-size thermocycler (Technique, UK) and the expected amplicon sizes were successfully generated. PCR amplification of ESBL genes *bla*_{CTX-M}

and *bla*_{SHV} was performed with Taq DNA polymerase (Thermo-Fisher Inc.) using published primers²⁷. Amplicons were sequenced (ACGT, Wheeling, IL, USA) by the chain termination method (Sanger sequencing) and sequences confirmed through BLAST-searching at NCBI. Phylogenetic group typing of *E. coli* was done according to the method of Clermont et al, in which PCR of a combination of two genes (*chuA* & *yjaA*) and an anonymous DNA fragment are used to classify strains²⁸.

Data analysis

The data were double entered for validation using EPIDATA software version 3.1, cleaned and exported to STATA (v14) for analysis. Data were compared across the districts using descriptive statistics, frequencies and bivariate analyses (cross-tabulations). Associations between outcome variables, i.e. isolates with ESBL/pAmpC genes, and categorical independent variables, i.e. socio-demographics, use of antibiotics, history of hospital admission and medical procedures three months prior to visits, were tested using Pearson's Chi-square. A significant level was set at $p < 0.05$. Similarly, odds ratios (ORs) between the categorical independent variables and outcome variables were determined. Variables with $p < 0.2$ at bivariate analysis were entered into multivariate logistic regression models with backward elimination. Independent variables used were gender (male vs. female), health center level, health sub-district and district, history of admission, history of medical procedures and antibiotic use recalled by client and from health record during the previous three months. To control for the effect of clustering, regression with robust standard errors was used.

Ethical statement

The study protocol and consent procedure were reviewed and approved by the Research Ethics Committee and the Higher Degrees committee of Makerere University Medical School (IRB #–2006-009) and the Uganda National Council for Science and Technology (HS246). All adult participants and guardians gave written informed consent before participation. The consent process included storage and use of the collected stool and urine samples for further studies. We obtained assent from participants below the age of 18 years in addition to informed consent from their parent/guardians/caregivers.

Results

Demographic characteristics, bacterial isolates

Of the 1,448 participants we enrolled, females were the majority i.e. 63.3% (913/1,448). Thirty three percent of the participants (474/1,448) were from Kampala, 35% (508/1,448) from Kayunga and 32% (466/1,448) from Mpigi. Around 56% (802/1,448) of the participants were in the 15–44-year age group (Table S1, *Extended data*²⁹).

From the 730 stool and 718 urine samples processed, 985 enterobacteria were isolated, of which 94.4% (930/985) were *E. coli* and 5.6% (55/985) were *K. pneumoniae*. Per district, 58% (274/474) of the enterobacteria were from Kampala, 80% (406/508) from Kayunga, and 65.5% (305/466) from Mpigi. The characteristics of the participants whose samples grew *E. coli*

and *K. pneumoniae* are shown in Table S2 (see *Extended data*²⁹). None of the urine samples grew bacteria at $\geq 10^4$ colony forming units (CFU) per milliliter implying that there was no infection-related growth. Overall, 37% (535/1,448) of the participants visited outpatient clinics for general conditions and bacteria grew in 68% (363/535) of these participants. Of the 731 participants who presented with infectious conditions, 67% (488/731) had bacterial growth in their samples. Of the 122 participants who visited HIV/AIDS clinics for routine checks, 72% (88/122) had growth (Tables S1 and S2, *Extended data*²⁹). Furthermore, 1,093 participants reported to have taken antibiotics three months prior to the visit, of whom 69% (755/1,093) had growth. Of the 125 participants who reported to have been previously admitted to hospitals, 62% (78/125) had growth. Of the 130 participants who reported to have undergone medical procedures three months prior to the clinic visit, 55% (71/130) had growth (Tables S1 and S2, *Extended data*²⁹).

Prevalence of AmpC β -lactamase producing isolates

Of the 985 bacterial isolates investigated, 21% (209/985) were cefoxitin resistant. However, 25 cefoxitin resistant isolates were not available at the time of analysis, leaving 184 isolates that were investigated, of which 70% (129/184) were AmpC

β -lactamase producers, while 30% (55/184) were non-producers (Figure 1). Therefore, the prevalence of AmpC β -lactamase producers among cefoxitin resistant isolates was 70% (129/184), implying the overall prevalence of AmpC β -lactamase producing isolates among enterobacteria was 13.1% (129/985); 12.5% (116/930 *E. coli* and 23.6% (13/55) *Klebsiella*. Per district the prevalence of AmpC β -lactamase producing bacteria was 23.7% (65/274) Kampala, 12.1% (37/305) Mpigi, and 6.7% (27/406) Kayunga. Furthermore, given the association between AmpC β -lactamases and clavulanate resistance, 247 amoxicillin/clavulanate resistant isolates in this study (see below) comprising of 229 *E. coli* and 18 *Klebsiella*, were tested for cefoxitin resistance, majority of which i.e. 84.6% (209/247) were found to be cefoxitin resistant while only 15.4% (38/247) were cefoxitin susceptible. Of the 209 amoxicillin/clavulanate and cefoxitin resistant isolates, 61.7% (129/209) were AmpC producers (Figure 1).

Prevalence of pAmpC β -lactamase genes

Of 129 cefoxitin resistant and AmpC β -lactamase producing isolates, 111 were tested for pAmpC β -lactamase gene carriage. Of these, 60% (67/111) carried pAmpC genes. Furthermore, 47 of the 55 AmpC β -lactamase non-producers (see above) were

Figure 1. Study flow chart.

tested for pAmpC gene carriage as they were cefoxitin resistant (MIC ≥ 16 $\mu\text{g/ml}$). Of these, 38% (18/47) carried pAmpC genes. Therefore, 54% (85/158) of the cefoxitin resistant isolates in this study (111 AmpC β -lactamase producers plus 47 AmpC β -lactamase non-producers) carried pAmpC β -lactamase genes. Isolates with reduced susceptibility to third-generation cephalosporins are suspects for AmpC β -lactamase production; in this study, 33.8% (22/65) of such isolates were cefoxitin susceptible, of which 59% (13/22) carried pAmpC genes. Overall, a total of 180 isolates (158 cefoxitin resistant plus 22 cefoxitin susceptible with reduced susceptibility to third-generation cephalosporins), comprising of 157 *E. coli* and 23 *Klebsiella*, were tested for pAmpC gene carriage (Figure 1). Of these, 54% (cefexitin resistant isolates, 85/158) were pAmpC positive while 59.1% (cefexitin susceptible isolates with reduced susceptibility to third-generation cephalosporins, 13/22) were pAmpC positive, giving a total of 98 pAmpC positive isolates detected.

The overall prevalence of pAmpC genes in enterobacteria was 10% (98/985); by district it was 16.4% (45/274) in Kampala, 6.2% (25/406) Kayunga and 9.2% (28/305) Mpigi; hence,

the urban district of Kampala had more pAmpC gene positive bacteria. Per species the prevalence of pAmpC genes among cefoxitin resistant and/or amoxicillin/clavulanate resistant isolates was 59% (93/157) in *E. coli* and 26.1% (5/23) in *Klebsiella*. pAmpC β -lactamase gene carriage correlated with AmpC β -lactamase production ($\chi^2 = 11.7$, P-value 0.0003). The pAmpC β -lactamase producing *E. coli* belonged to phylogenetic groups A (n=23), B1 (n=10), B2 (n=35) and D (n=25). Overall, 39.6% (44/111) of AmpC β -lactamase producing isolates did not carry pAmpC genes, of which eight were *Klebsiella* that do not carry chromosomal AmpC genes. The AmpC β -lactamase producing isolates of *E. coli* that were pAmpC negative were assumed to be hyper-producers of chromosomal AmpC β -lactamases. Relatedly, the AmpC β -lactamase producing isolates of *Klebsiella* that were pAmpC negative likely carried genes we did not screen for. The characteristics of participants who carried pAmpC gene-positive bacteria are shown in Table 1.

The pAmpC genes detected were *bla*_{CIT} (n=54), *bla*_{CMY-2} (n=23), *bla*_{CMY-4} (n=31), *bla*_{EB} (n=51, mainly *bla*_{ACT-1}) and *bla*_{DHA} (n=20), Table 2. Twenty-two isolates carried ≥ 2 pAmpC genes and the

Table 1. Characteristics of participants who carried pAmpC gene positive bacteria.

Characteristics	pAmpC		
	Not present, n (%)	Present, n (%)	p-value
Age group			
0–14	260 (31.8)	36 (36.7)	0.131
15–44	440 (53.9)	55 (56.1)	
45+	117 (14.3)	7 (7.2)	
Sex			
Female	544 (66.5)	59 (60.2)	0.214
Male	274 (33.5)	39 (39.8)	
Health center level			
National referral	75 (9.1)	18 (18.4)	0.023
General hospital	220 (26.8)	28 (28.6)	
Health center IV	134 (16.3)	11 (11.2)	
Health center III	392 (47.8)	41 (41.8)	
District			
Kampala	198 (24.1)	44 (44.9)	<0.001
Kayunga	363 (44.2)	25 (25.5)	
Mpigi	260 (31.7)	29 (29.6)	
Reason for visit			
ISS	76 (9.8)	5 (5.3)	0.350
Infection	398 (51.2)	50 (52.6)	

Characteristics	pAmpC		
	Not present, n (%)	Present, n (%)	p-value
General	303 (39.0)	40 (42.1)	
History of admission			
No	748 (92.4)	86 (88.7)	0.207
Yes	62 (7.6)	11 (11.3)	
History of medical procedures			
Contact	4 (7.3)	1 (14.2)	(omitted)
Inoculation	40 (72.7)	3 (42.9)	
Surgery	11 (20.0)	3 (42.9)	
Use of antibiotics			
No	194 (23.6)	24 (24.5)	(omitted)
Yes	627 (76.4)	74 (75.5)	
Use of penicillin			
No	427 (67.8)	53 (73.6)	0.313
Yes	203 (32.2)	19 (26.4)	
Use of ciprofloxacin			
No	566 (89.8)	59 (80.8)	0.020
Yes	64 (10.2)	14 (19.2)	
Use of cotrimoxazol (septrin)			
No	239 (34.3)	34 (40.0)	0.297
Yes	458 (65.7)	51 (60.0)	

ISS, immune suppression syndrome (HIV/AIDS).

most frequent combination was bla_{EBC} plus bla_{CTT} . Furthermore, in this study, 11 ESBL producing isolates carried $bla_{CTX-M-15}$ while three carried $bla_{CTX-M-28}$. Co-existence of pAmpC with betalactamase genes (bla_{CTX-M} , bla_{SHV} , bla_{TEM}) occurred in 49% (48/98), 9.2% (9/98) and 34.7% (34/98) isolates, respectively. Figure 2 depicts the distribution of β -lactamase genotypes in the three districts.

Antibiotic resistance patterns

Generally, cefoxitin resistance varied across the three districts and the variation was statistically significant ($p=0.023$), Table S3 (see *Extended data*²⁹). Furthermore, 59% (58/98) of the pAmpC β -lactamase producing isolates were resistant to a β -lactam antibiotic and to two other classes of commonly used non- β -lactam antibiotics, implying they were MDR³⁰. Two of the isolates were

Table 2. Prevalence of pAmpC β -lactamase genes among *E. coli* and *Klebsiella* across the three districts.

pAmpC gene ^a	Specimen type (N=98)		District			Total ^b
	Stool 55 (56%)	Urine 43 (44%)	Kampala 45/274 (16.4%)	Kayunga 25/406 (6.2%)	Mpigi 28/305 (9.2%)	
bla_{CTT}	30	24	25 (13/12)	12 (2/10)	17 (8/9)	54
bla_{DHA}	10	10	5	8	7	20
bla_{EBC}	28	23	28	11	12	51

^aBased on a multiplex PCR by Perez-Perez and Hanson, 2002; ^bNumbers are derived from specimen type.

Figure 2. Distribution of β -lactamase genotypes in the three districts of Kampala, Kayunga and Mpigi.

resistant to co-trimoxazole, ciprofloxacin, gentamicin, nitrofurantoin and chloramphenicol, while seven were co-resistant to these drugs excluding nitrofurantoin, and one was resistant to the same drugs except chloramphenicol. Resistance to ciprofloxacin, co-trimoxazole and gentamicin was noted in nine isolates, co-trimoxazole and chloramphenicol in 22 and co-trimoxazole and gentamicin in five. Resistance to individual antibiotics among the pAmpC β -lactamase gene positive isolates was as follows, co-trimoxazole 79% (77/98); chloramphenicol 34.5%

(34/98); ciprofloxacin 28% (27/98); gentamicin 23.5% (23/98); nitrofurantoin 8% (8/98); piperacillin/tazobactam 30.6% (30/98). None of the isolates were resistant to carbapenems.

Factors associated with carriage of pAmpC β -lactamase producing bacteria

There was significant association between health center level, district of residence, use of ciprofloxacin and sample type with carriage of pAmpC β -lactamase producing bacteria, [Table 3](#).

Table 3. Factors associated with carriage of pAmpC β -lactamase producing bacteria.

Characteristic	pAmpC gene				
	Not present, n (%)	Present, n (%)	p-value	cOR (95% CI)	aOR (95% CI)
Age group					
0–14	260 (31.8)	36 (36.7)	0.131	1.0	1.0
15–44	440 (53.9)	55 (56.1)		0.90 (0.58, 1.41)	0.59 (0.32, 1.07)
45+	117 (14.3)	7 (7.2)		0.43 (0.19, 1.00)*	0.17 (0.05, 0.62)*
Gender					
Female	544 (66.5)	59 (60.2)	0.214	1.0	1.0
Male	274 (33.5)	39 (39.8)		1.31 (0.85, 2.02)	1.48 (0.85, 2.56)
Health center level					
National Referral	75 (9.1)	18 (18.4)	0.023	1.0	1.0
General Hospital	220 (26.8)	28 (28.6)		0.53 (0.28, 1.01)	1.04 (0.40, 2.70)
Health Center IV	134 (16.3)	11 (11.2)		0.34 (0.15, 0.76)*	1.53 (0.47, 5.00)
Health Center III	392 (47.8)	41 (41.8)		0.44 (0.24, 0.80)*	0.74 (0.28, 1.98)
District					
Kampala ^a	198 (24.1)	44 (44.9)	<0.001	1.0	1.0
Kayunga ^b	363 (44.2)	25 (25.5)		0.31 (0.18, 0.52)	0.23 (0.11, 0.47)*
Mpigi ^c	260 (31.7)	29 (29.6)		0.50 (0.30, 0.83)*	0.49 (0.25, 0.99)*
Reason for visit					
ISS	76 (9.8)	5 (5.3)	0.350	1.0	1.0
Infection	398 (51.2)	50 (52.6)		1.91 (0.74, 4.94)	2.60 (0.73, 9.32)
General	303 (39.0)	40 (42.1)		2.01 (0.77, 5.26)	3.20 (0.86, 11.86)
History of admission					
No	748 (92.4)	86 (88.7)	0.207	1.0	1.0
Yes	62 (7.6)	11 (11.3)		1.54 (0.78, 3.04)	0.55 (0.21, 1.49)
History of medical procedures					
Contact	4 (7.3)	1 (14.2)	0.178		
Inoculation	40 (72.7)	3 (42.9)			
Surgery	11 (20.0)	3 (42.9)			

Characteristic	pAmpC gene				
	Not present, n (%)	Present, n (%)	p-value	cOR (95% CI)	aOR (95% CI)
Antibiotic use (any)					
No	194 (23.6)	24 (24.5)	0.850		
Yes	627 (76.4)	74 (75.5)			
Use of penicillin					
No	427 (67.8)	53 (73.6)	0.313		
Yes	203 (32.2)	19 (26.4)			
Use of ciprofloxacin					
No	566 (89.8)	59 (80.8)	0.020	1.0	1.0
Yes	64 (10.2)	14 (19.2)		2.10 (1.11, 3.97)	2.61 (1.28, 5.32)
Use of co-trimoxazole					
No	239 (34.3)	34 (40.0)	0.297		
Yes	458 (65.7)	51 (60.0)			

cOR, crude odds ratio; aOR, adjusted odds ratio; ISS, immune suppression syndrome (HIV/AIDS); *Statistically significant association.

After adjusting for each of them, the district of residence remained an independent risk factor for carriage of pAmpC β -lactamase producing bacteria, Table 3. Overall, we found that residing in a rural district (Kayunga/Mpigi) was associated with low carriage of pAmpC β -lactamase producing bacteria (aOR 0.23 (95% CI:0.11, 0.47) and aOR 0.49 (95% CI:0.25, 0.99), respectively). Similarly, participants who were 45 years and above carried less pAmpC positive bacteria (aOR 0.17; 95% CI:0.05, 0.62). Ciprofloxacin use was an independent risk factor for carriage of pAmpC positive bacteria (aOR 2.61; 95% CI:1.28, 5.32), Table 3.

Discussion

AmpC β -lactamases are clinically important in that community-acquired infections arising from strains producing these enzymes may not respond to empiric treatment with common antibiotics. The cefoxitin/cloxacillin double-disc synergy screening of cefoxitin and amoxicillin/clavulanate resistant isolates for AmpC β -lactamase production is a simple and efficient method of quickly detecting these resistance mechanisms in isolates^{21,22}. Using this approach, the prevalence of AmpC β -lactamase producing bacteria in this study (13.2%), and the prevalence of pAmpC β -lactamase gene carriage (26-59%) was high but comparable to the rate of 36.5% at Mbarara Regional Referral Hospital in South-western Uganda²⁰. The prevalence in our study is higher than rates from other East African settings³¹⁻³³, however, the study populations were varied, making direct comparison difficult. Furthermore, in this study, co-carriage rates of ESBL- and pAmpC genes was high, which is a cause for concern as individuals carrying strains producing these enzymes could be reservoirs of spread for MDR bacteria^{34,35}. A significant

number of isolates that were susceptible to third-generation cephalosporins but cefoxitin resistant carried pAmpC genes, a discordance that has been reported before^{3,36}. The overall carriage rate (10%) for pAmpC genes in enterobacteriaceae in this study reflects extensive use of antibiotics, as found in Libya where a fecal carriage rate of 6.7% for pAmpC β -lactamase producing bacteria in the community was reported³⁷. Importantly, ceftriaxone has been used in Uganda for the last two decades, mainly in empirical treatment of systemic bacterial infections and currently its prescription among in-patients is higher than that of other antibiotics³⁸. Such extensive use of ceftriaxone could be a driving force behind the high pAmpC gene carriage rates. Coexistence between *bla*_{EBC} and *bla*_{CTT} genes in isolates has been reported before in Africa and Asia^{36,39}. *bla*_{CTT} reported in this study comprised of the *bla*_{CMY-2} and *bla*_{CMY-4} genes. In Africa, *bla*_{CMY-4} was first reported in North Africa. The detection of *bla*_{DHA} and *bla*_{EBC} genes is of concern as *bla*_{ACT-1}, a prototype gene for the *bla*_{EBC} and *bla*_{DHA} genes, is linked to a functional *ampR* regulator and is inducible^{40,41}. In Seoul, Korea, four of the five deaths from bloodstream infections due to *bla*_{DHA} producing *K. pneumoniae* were associated with treatment with extended spectrum cephalosporins⁴².

In this study, about half of the isolates exhibiting reduced susceptibility to third-generation cephalosporins carried pAmpC β -lactamase genes, which contrasted findings from Northern Europe where 100% of isolates exhibiting reduced susceptibility to third-generation cephalosporins carried pAmpC genes²³. Furthermore, 73% of cefoxitin resistant and pAmpC positive isolates were susceptible to third-generation cephalosporins, in contrast with 26% (10/38) reported from Switzerland, for pAmpC

producing isolates that were susceptible to third-generation cephalosporins⁴³. Overall, findings in this study suggest that antibiotic susceptibility testing of enterobacteria in Uganda may yield false results for third-generation cephalosporins e.g. ceftriaxone, cefotaxime and ceftazidime. Given that bacterial isolates are not routinely tested for AmpC β -lactamase production, region specific protocols guided by surveillance data are necessary.

In *E. coli*, phylogenetic group analysis has been used to differentiate virulent/extra-intestinal strains, which predominantly belong to phylogenetic groups B2 and D, from commensal strains that belong to groups A and B1²⁸. In this study, the predominance of groups B2 and D (n=60) compared to groups A and B1 (n=33) in the community is cause for concern as they are associated with pathogenicity, implying that strains with potential to cause extra-intestinal disease are prevalent, supporting the notion that occurrence of pAmpC β -lactamase producing strains in the community is of public health concern^{44,45}. One limitation in this study was that we were not able to genotype isolates with internationally acceptable procedures like the multilocus sequence typing (MLST) to determine the sequence types.

Conclusions

AmpC β -lactamase production and pAmpC β -lactamase encoding genes are prevalent among *E. coli* and *K. pneumoniae* isolates from urban and rural dwellers in Uganda. As pAmpC genes are easily transferrable between species and have been associated with outbreaks of community- and hospital-acquired infections, pAmpC beta-lactamase producing bacteria may represent a threat in low-income settings. There is need for testing for ceftazidime resistance during routine antibiotic susceptibility testing, especially among isolates that are resistant to amoxicillin/clavulanate, as well as isolates that are susceptible to third-generation cephalosporins.

Data availability

Underlying data

Figshare: Underlying data for manuscript “Prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteria isolated from urban and rural folks in Uganda” by Najjuka FC *et al.* <https://doi.org/10.6084/m9.figshare.13259984>²⁹.

This project contains the following underlying data:

- Participants_recruited_from_outpatient_clinics.xls (participant data underlying Table S1)
- Participants_whose_samples_had_growth.xls (participant data underlying Table S2)
- Susceptibility profile of PampC-isolates-09092020-1.xls (antibiotic susceptibility data underlying Table S3)
- Table of ceftazidime resistant-susceptible Isolates.xls (ceftazidime resistance data underlying Table S3)

Extended data

Figshare: Extended data for manuscript “Prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteria isolated from urban and rural folks in Uganda” by Najjuka FC *et al.* <https://doi.org/10.6084/m9.figshare.13259984>²⁹.

This project contains the following extended data:

- Table S1.docx (Characteristics of participants attending OPDs in the three study sites)
- Table S2.docx (Characteristics of participants with bacterial growth on culturing (n=985))
- Table S3.docx (Antibiotic resistance rates among *E. coli* and *Klebsiella* isolated from individuals attending outpatient clinics in Kampala, Kayunga and Mpigi districts (2007–2008))

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

The E-test strips were provided by AB Biodisc Solna, Sweden at discount price. For technical assistance, we thank Jacent Nassuna, Edgar Kigozi & Moses Okee (Dept. of Medical Microbiology, Makerere University) and Mugabe Pallen. For administrative assistance we thank Geraldine Nalwadda. The reported work was conducted by CFN in partial fulfillment of the requirements for the award of the degree of Doctor of Philosophy of Makerere University.

References

1. Seni J, Najjuka CF, Kateete DP, *et al.*: **Antimicrobial resistance in hospitalized surgical patients: a silently emerging public health concern in Uganda.** *BMC Res Notes*. 2013; **6**: 298.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Reuland EA, Halaby T, Hays JP, *et al.*: **Plasmid-Mediated AmpC: Prevalence in Community-Acquired Isolates in Amsterdam, the Netherlands, and Risk Factors for Carriage.** *PLoS One*. 2015; **10**(1): e0113033.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Drinkovic D, Morris AJ, Dyet K, *et al.*: **Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.** *NZ Med J*. 2015; **128**(1410): 50–59.
[PubMed Abstract](#)
4. Jacoby GA: **AmpC beta-lactamases.** *Clin Microbiol Rev*. 2009; **22**(1): 161–182.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Tan TY, Ng LSY, He J, *et al.*: **Evaluation of screening methods to detect**

- plasmid-mediated AmpC in *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis*. *Antimicrob Agents Chemother*. 2009; **53**(1): 146–149. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Pérez-Pérez FJ, Hanson ND: Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol*. 2002; **40**(6): 2153–2162. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 7. Philippon A, Arlet G, Jacoby GA: Plasmid-determined AmpC-type beta-lactamases. *Antimicrob Agents Chemother*. 2002; **46**(1): 1–11. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 8. Medeiros AA, Cohenford M, Jacoby GA: Five novel plasmid-determined beta-lactamases. *Antimicrob Agents Chemother*. 1985; **27**(5): 715–719. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 9. Rodríguez-Baño J, Miró E, Villar M, et al.: Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β -lactamases. *J Infect*. 2012; **64**(2): 176–183. [PubMed Abstract](#) | [Publisher Full Text](#)
 10. Hara GL, Gould I, Endimiani A, et al.: Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. *J Chemother*. 2013; **25**(3): 129–140. [PubMed Abstract](#) | [Publisher Full Text](#)
 11. Okoche D, Asimwe BB, Katabazi FA, et al.: Prevalence and Characterization of Carbapenem-Resistant Enterobacteriaceae Isolated from Mulago National Referral Hospital, Uganda. *PLoS One*. 2015; **10**(8): e0135745. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 12. Ohana S, Leflon V, Ronco E, et al.: Spread of a *Klebsiella pneumoniae* strain producing a plasmid-mediated ACC-1 AmpC beta-lactamase in a teaching hospital admitting disabled patients. *Antimicrob Agents Chemother*. 2005; **49**(5): 2095–2097. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 13. Roh KH, Uh Y, Kim JS, et al.: First outbreak of multidrug-resistant *Klebsiella pneumoniae* producing both SHV-12-type extended-spectrum beta-lactamase and DHA-1-type AmpC beta-lactamase at a Korean hospital. *Yonsei Med J*. 2008; **49**(1): 53–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. Najjuka CF, Kateete DP, Kajumbula HM, et al.: Antimicrobial susceptibility profiles of *Escherichia coli* and *Klebsiella pneumoniae* isolated from outpatients in urban and rural districts of Uganda. *BMC Res Notes*. 2016; **9**(1): 235. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Scott E, Bloomfield SF: The survival and transfer of microbial contamination via cloths, hands and utensils. *J Appl Bacteriol*. 1990; **68**(3): 271–278. [PubMed Abstract](#) | [Publisher Full Text](#)
 16. Pidwirny M: Fundamentals of physical geography. *Date Viewed*. 2006; **19**: 2009.
 17. Clinical, Institute LS: Clinical Laboratory Standards Institute, Wayne PA, USA: CLSI; 2007.
 18. Rensing KL, Abdallah HM, Koek A, et al.: Prevalence of plasmid-mediated AmpC in Enterobacteriaceae isolated from humans and from retail meat in Zagazig, Egypt. *Antimicrob Resist Infect Control*. 2019; **8**(1): 45. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. Li Y, Li Q, Du Y, et al.: Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. *J Clin Microbiol*. 2008; **46**(4): 1317–1321. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Nakaye M, Bwanga F, Itabangi H, et al.: Amp C-BETA Lactamases among Enterobacteriaceae Isolated at a Tertiary Hospital, South Western Uganda. *Br Biotechnol J*. 2014; **4**(9): 1026–1036. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Maraskolhe DL, Deotale VS, Mendiratta DK, et al.: Comparison of Three Laboratory Tests for Detection of AmpC β Lactamases in *Klebsiella* Species and *E. Coli*. *J Clin Diagn Res*. 2014; **8**(6): DC05–DC08. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Polsfuss S, Bloemberg GV, Giger J, et al.: Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae. *J Clin Microbiol*. 2011; **49**(8): 2798–2803. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Reuland EA, Hays JP, de Jongh D, et al.: Detection and occurrence of plasmid-mediated AmpC in highly resistant gram-negative rods. *PLoS One*. 2014; **9**(3). [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. CLSI: Pennsylvania, USA: Clinical and Laboratory Standards Institute; 2007.
 25. Drieux L, Brossier F, Sougakoff W, et al.: Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. *Clin Microbiol Infect*. 2008; **14**(s1): 90–103. [PubMed Abstract](#) | [Publisher Full Text](#)
 26. Zhao S, White DG, McDermott PF, et al.: Identification and expression of cephamycinase bla(CMY) genes in *Escherichia coli* and *Salmonella* isolates from food animals and ground meat. *Antimicrob Agents Chemother*. 2001; **45**(12): 3647–3650. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Kiratisin P, Apisarnthanarak A, Laesripa C, et al.: Molecular Characterization and Epidemiology of Extended-Spectrum- β -Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolates Causing Health Care-Associated Infection in Thailand, Where the CTX-M Family Is Endemic. *Antimicrob Agents Chemother*. 2008; **52**(8): 2818–2824. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Clermont O, Bonacorsi S, Bingen E: Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol*. 2000; **66**(10): 4555–4558. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Najjuka FC, Kateete D, Lodiongo DK, et al.: Extended data for manuscript "Prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteria isolated from urban and rural folks in Uganda" by Najjuka FC et al. *figshare*. Dataset. 2020. <http://www.doi.org/10.6084/m9.figshare.13259984>
 30. Naseer U, Haldorsen B, Simonsen G, et al.: Sporadic occurrence of CMY-2-producing multidrug-resistant *Escherichia coli* of ST-complexes 38 and 448, and ST131 in Norway. *Clin Microbiol Infect*. 2010; **16**(2): 171–178. [PubMed Abstract](#) | [Publisher Full Text](#)
 31. Tellevik MG, Blomberg B, Kommedal Ø, et al.: High Prevalence of Faecal Carriage of ESBL-Producing Enterobacteriaceae among Children in Dar es Salaam, Tanzania. *PLoS One*. 2016; **11**(12): e0168024. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Kiiru J, Kariuki S, Goddeeris BM, et al.: Analysis of β -lactamase phenotypes and carriage of selected β -lactamase genes among *Escherichia coli* strains obtained from Kenyan patients during an 18-year period. *BMC Microbiol*. 2012; **12**: 155. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Taitt CR, Leski TA, Erwin DP, et al.: Antimicrobial resistance of *Klebsiella pneumoniae* stool isolates circulating in Kenya. *PLoS One*. 2017; **12**(6): e0178880. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Hanson ND, Moland ES, Hong S, et al.: Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 β -lactamases in urine isolates of *Klebsiella pneumoniae* and *Escherichia coli* in a US community. *Antimicrob Agents Chemother*. 2008; **52**(10): 3814–3816. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Wiener J, Quinn JP, Bradford PA, et al.: Multiple antibiotic-resistant *Klebsiella* and *Escherichia coli* in nursing homes. *JAMA*. 1999; **281**(6): 517–523. [PubMed Abstract](#) | [Publisher Full Text](#)
 36. Zorhani A, Daw H, Sufya N, et al.: Co-Occurrence of Plasmid-Mediated AmpC β -Lactamase Activity Among *Klebsiella pneumoniae* and *Escherichia coli*. *Open Microbiol J*. 2017; **11**: 195–202. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Ahmed SF, Ali MMM, Mohamed ZK, et al.: Faecal carriage of extended-spectrum β -lactamases and AmpC-producing *Escherichia coli* in a Libyan community. *Ann Clin Microbiol Antimicrob*. 2014; **13**: 22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Kiguba R, Karamagi C, Bird SM: Extensive antibiotic prescription rate among hospitalized patients in Uganda: but with frequent missed-dose days. *J Antimicrob Chemother*. 2016; **71**(6): 1697–1706. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Abdulaziz Z: Co-occurrence of plasmid-mediated AmpC β -lactamase activity among *Klebsiella pneumoniae* and *E. coli*. *Open Microbiol J*. 2017; **11**: 195–202. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Jacoby GA: AmpC β -lactamases. *Clin Microbiol Rev*. 2009; **22**(1): 161–182. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Hsieh WS, Wang NY, Feng JA, et al.: Identification of DHA-23, a novel plasmid-mediated and inducible AmpC beta-lactamase from Enterobacteriaceae in Northern Taiwan. *Front Microbiol*. 2015; **6**: 436. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Pai H, Kang CI, Byeon JH, et al.: Epidemiology and Clinical Features of Bloodstream Infections Caused by AmpC-Type- β -Lactamase-Producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2004; **48**(10): 3720–3728. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Conen A, Frei R, Adler H, et al.: Microbiological Screening Is Necessary to Distinguish Carriers of Plasmid-Mediated AmpC Beta-Lactamase-Producing Enterobacteriaceae and Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae because of Clinical Similarity. *PLoS One*. 2015; **10**(3): e0120688. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Pitout JD: Enterobacteriaceae that produce extended-spectrum beta-lactamases and AmpC beta-lactamases in the community: the tip of the iceberg? *Curr Pharm Des*. 2013; **19**(2): 257–263. [PubMed Abstract](#)
 45. Pitout JD, Gregson DB, Church DL, et al.: Population-based laboratory surveillance for AmpC β -lactamase-producing *Escherichia coli*, Calgary. *Emerg Infect Dis*. 2007; **13**(3): 443–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ? ✓ ?

Version 1

Reviewer Report 06 September 2021

<https://doi.org/10.21956/aasopenres.14270.r28822>

© 2021 Qamar M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Muhammad Usman Qamar

Department of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan

The authors did a comprehensive study on the prevalence of AMR in animals. This topic is the need of the hour. Overall, the study is appropriate and should be accepted for indexing.

1. Change the word Enterobacteriaceae to Enterobacterales.
2. Review the English grammar mistakes
3. The Discussion part should be more elaborate.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: I have been working on One Health AMR agenda. I am mainly working on molecular epidemiology of AMR, characterization, and risk factors associated with AMR.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 06 September 2021

<https://doi.org/10.21956/aasopenres.14270.r28846>

© 2021 Kariuki S et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Samuel Kariuki

Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya

Robert Onsare

Kenya Medical Research Institute (KEMRI), Nairobi, Kenya

The study was aimed at estimating the prevalence of pAmpC β -lactamase producing bacteria among Enterobacteriaceae isolated from individuals attending outpatient clinics in Kampala city and two rural districts in central Uganda.

The study found that pAmpC beta-lactamase producing enterobacteria are prevalent in urban and rural dwellers in Uganda and recommended that cefoxitin should be considered during routine susceptibility testing in this setting.

The article is well written, with appropriate citations and the methodology adequately answers the study questions. The conclusions made are adequately supported by the results.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology of infectious diseases and antimicrobial resistance of tropical infections

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 07 July 2021

<https://doi.org/10.21956/aasopenres.14270.r28723>

© 2021 Ngoi S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Soo Tein Ngoi

Department of Medical Microbiology, University Malaya, Kuala Lumpur, Malaysia

The study presented a detailed analysis of the prevalence of AmpC beta-lactamase producers, pAmpC and ESBL genes in the two most common enteric bacterial species, *E. coli* and *K. pneumoniae*. The authors observed a relatively higher prevalence of AmpC producers in urban areas than in rural areas. Detailed molecular characterization was performed to identify the pAmpC and ESBL genotypes, and a great diversity of the beta-lactamase genes was observed among the strains. Moreover, the common carriage of beta-lactamase-producing and potentially virulent *E. coli* strains in the population indeed poses a great threat to public health, not only causing infections in susceptible hosts but also serves as a reservoir for spreading antimicrobial resistance genes among the pathogenic bacteria. This study adds knowledge to the molecular epidemiology of beta-lactamase-producing enteric bacteria, which is one of the main concerns pertaining to the rising trend of antimicrobial-resistant organisms. However, the authors should make the following changes:

1. The sampling design and procedures, bacterial isolation, antimicrobial susceptibility testing, and phenotypic detection of AmpC and ESBL producers have already been reported in detail in the previous article published by the authors ¹. Please remove the related sections in Methods and Results to avoid duplication of data. I suggest the authors include a summary of the previous findings in the last paragraph of the Introduction since this study is considered an extension of the previously reported work.
2. Figure 2 clearly depicts the distribution of the different *bla* genotypes according to geographical regions. This is very interesting as there seems to be a predominance of specific *bla* genes in the different districts. Could the authors elaborate more on this finding? Statistical analysis could be done to determine if the correlation between the

genotypes and the geographical regions is significant or not. Also, the figure legends should be standardized to ease viewing.

3. Ciprofloxacin use was found to be a risk factor for the carriage of pAmpC-positive strains. It would be of interest if the authors could discuss the use of fluoroquinolones in the region.

Minor comments:

1. Please standardize the nomenclature of *K. pneumoniae* throughout the text.
2. The family name, *Enterobacteriaceae*, should be capitalized and italicized.

References

1. Najjuka CF, Kateete DP, Kajumbula HM, Joloba ML, et al.: Antimicrobial susceptibility profiles of *Escherichia coli* and *Klebsiella pneumoniae* isolated from outpatients in urban and rural districts of Uganda. *BMC Res Notes*. 2016; **9**: 235 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Antimicrobial resistance; bacterial genomics; molecular epidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Aug 2021

David Kateete, Makerere University College of Health Sciences, Kampala, Uganda

Response to comments:

Thank you for your insightful comments. We are using these to improve our manuscript. Please find below, our response to each of the raised concerns. Kindly note that we are awaiting an additional reviewer's report to upload the revised manuscript hence, the changes to the manuscript in light of your suggestions will be seen when we upload the revised manuscript.

Comment 1:

The sampling design and procedures, bacterial isolation, antimicrobial susceptibility testing, and phenotypic detection of AmpC and ESBL producers have already been reported in detail in the previous article published by the authors ¹. Please remove the related sections in Methods and Results to avoid duplication of data. I suggest the authors include a summary of the previous findings in the last paragraph of the Introduction since this study is considered an extension of the previously reported work.

Response:

We agree. We have revised the Introduction accordingly.

Comment 2:

Figure 2 clearly depicts the distribution of the different *bla* genotypes according to geographical regions. This is very interesting as there seems to be a predominance of specific *bla* genes in the different districts. Could the authors elaborate more on this finding? Statistical analysis could be done to determine if the correlation between the genotypes and the geographical regions is significant or not. Also, the figure legends should be standardized to ease viewing.

Response:

Again, thanks for your appreciation of our analysis of the *bla* genotypes according to geographical distribution. We repeated the statistical analysis as advised; however, the results showed no statistically significant correlation between the genotypes and the geographical regions i.e., none of the enzymes was significantly in greater proportion compared to others across the different districts (p-value = 0.208). The figure legends are now standardized and easily viewable.

Comment 3:

Ciprofloxacin use was found to be a risk factor for the carriage of pAmpC-positive strains. It would be of interest if the authors could discuss the use of fluoroquinolones in the region.

Response:

As advised, in our revised manuscript we have discussed the use of fluoroquinolones in Uganda and generally the East African region.

Minor comments:

- Please standardize the nomenclature of *K. pneumoniae* throughout the text.

- The family name, *Enterobacteriaceae*, should be capitalized and italicized.

Response:

We have standardized the nomenclature of *Klebsiella pneumoniae*, and italicized the name *Enterobacteriaceae*. We thank you.

Competing Interests: No competing interests to disclose.